NI201900053A - Formas cristalinas de un inhibidor de magl - Google Patents
Formas cristalinas de un inhibidor de maglInfo
- Publication number
- NI201900053A NI201900053A NI201900053A NI201900053A NI201900053A NI 201900053 A NI201900053 A NI 201900053A NI 201900053 A NI201900053 A NI 201900053A NI 201900053 A NI201900053 A NI 201900053A NI 201900053 A NI201900053 A NI 201900053A
- Authority
- NI
- Nicaragua
- Prior art keywords
- crystal forms
- magl inhibitor
- magl
- inhibitor
- hexafluoropropan
- Prior art date
Links
- 229940122357 Monoacylglycerol lipase inhibitor Drugs 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- -1 1, 1, 1, 3, 3, 3-hexafluoropropan-2-yl Chemical group 0.000 abstract 1
- QUUVZQXSCVVGIY-UHFFFAOYSA-N [2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl piperazine-1-carboxylate Chemical compound N1(CCNCC1)C(=O)OCC1=C(C=C(C=C1)C(F)(F)F)N1CCCC1 QUUVZQXSCVVGIY-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423126P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201900053A true NI201900053A (es) | 2019-10-30 |
Family
ID=62145805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201900053A NI201900053A (es) | 2016-11-16 | 2019-05-16 | Formas cristalinas de un inhibidor de magl |
Country Status (38)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| CN109996790B (zh) | 2016-09-19 | 2023-05-16 | H.隆德贝克有限公司 | 哌嗪氨基甲酸酯及其制备和使用方法 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2017361254B2 (en) | 2016-11-16 | 2021-09-23 | H. Lundbeck A/S. | Pharmaceutical formulations |
| PE20191239A1 (es) | 2016-11-16 | 2019-09-16 | Abide Therapeutics Inc | Formas cristalinas de un inhibidor de magl |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| DK3630744T3 (da) | 2017-05-23 | 2023-03-06 | H Lundbeck As | Pyrazol-magl-inhibitorer |
| UA126685C2 (uk) | 2017-08-29 | 2023-01-11 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Сполуки, які є модуляторами magl, і способи їх отримання і застосування |
| EP3793547A4 (en) | 2018-05-15 | 2021-11-17 | H. Lundbeck A/S | MAGL INHIBITORS |
| MX2021000549A (es) * | 2018-07-19 | 2021-03-25 | Pfizer | Compuestos espiro heterociclicos como inhibidores de magl. |
| AU2019322538B2 (en) | 2018-08-13 | 2021-09-30 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| PL3883936T3 (pl) | 2018-11-22 | 2023-11-20 | F. Hoffmann-La Roche Ag | Nowe związki heterocykliczne |
| EP3914589A4 (en) * | 2019-01-25 | 2022-11-30 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
| WO2021097107A1 (en) * | 2019-11-15 | 2021-05-20 | Lundbeck La Jolla Research Center, Inc. | Crystalline forms of a magl inhibitor |
| AU2021259496A1 (en) | 2020-04-21 | 2022-11-10 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| WO2023092079A1 (en) * | 2021-11-19 | 2023-05-25 | Bryant Cynthia W | Use of cannabinoid compounds to treat gastrointestinal disorders |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
| IL316302A (en) | 2022-05-04 | 2024-12-01 | H Lundbeck As | Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor |
| CN117665187B (zh) * | 2023-11-23 | 2024-08-16 | 宁波大红鹰药业股份有限公司 | 一种舒林酸中间体杂质的测定方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| AU661080B2 (en) | 1991-11-22 | 1995-07-13 | Warner Chilcott Company, Llc | Risedronate delayed-release compositions |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| KR100291362B1 (ko) | 1992-10-16 | 2001-09-17 | 니뽄 신야쿠 가부시키가이샤 | 왁스매트릭스의제법 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| MXPA03005462A (es) | 2000-12-18 | 2003-09-25 | Novartis Ag | Combinacion terapeutica de amlodipina y benazepril. |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| CA2476936A1 (en) | 2002-02-20 | 2003-08-28 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| NZ560232A (en) | 2005-02-25 | 2010-11-26 | Hoffmann La Roche | Tablets with improved drug substance dispersibility |
| ES2812250T3 (es) | 2005-11-28 | 2021-03-16 | Marinus Pharmaceuticals Inc | Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas |
| EP1938804A1 (en) | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
| FR2938341A1 (fr) | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| CN101530399B (zh) | 2009-04-15 | 2011-01-26 | 江苏中兴药业有限公司 | 一种水飞蓟宾固体自乳化片 |
| MX350788B (es) * | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| US9567302B2 (en) | 2012-03-19 | 2017-02-14 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| US9321750B2 (en) | 2012-04-20 | 2016-04-26 | Innov17 Llc | ROR modulators and their uses |
| SMT202500078T1 (it) | 2012-11-02 | 2025-03-12 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| TW201446286A (zh) | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| MX2015017961A (es) | 2013-07-03 | 2016-10-14 | Abide Therapeutics Inc | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. |
| US20150064252A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| CN103893258B (zh) | 2013-12-05 | 2017-09-29 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
| WO2015164160A1 (en) | 2014-04-21 | 2015-10-29 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
| US10093630B2 (en) * | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2016149401A2 (en) | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| PE20191239A1 (es) | 2016-11-16 | 2019-09-16 | Abide Therapeutics Inc | Formas cristalinas de un inhibidor de magl |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2017361254B2 (en) | 2016-11-16 | 2021-09-23 | H. Lundbeck A/S. | Pharmaceutical formulations |
-
2017
- 2017-11-15 PE PE2019001013A patent/PE20191239A1/es unknown
- 2017-11-15 MA MA46866A patent/MA46866B1/fr unknown
- 2017-11-15 HU HUE21199077A patent/HUE064559T2/hu unknown
- 2017-11-15 US US16/349,142 patent/US11142517B2/en active Active
- 2017-11-15 ES ES17872429T patent/ES2900016T3/es active Active
- 2017-11-15 GE GEAP202315091A patent/GEAP202315091A/en unknown
- 2017-11-15 JO JOP/2019/0109A patent/JOP20190109B1/ar active
- 2017-11-15 LT LTEPPCT/US2017/061875T patent/LT3541807T/lt unknown
- 2017-11-15 AU AU2017361257A patent/AU2017361257B2/en not_active Ceased
- 2017-11-15 PL PL17872429T patent/PL3541807T3/pl unknown
- 2017-11-15 CN CN202210681321.7A patent/CN115093382A/zh active Pending
- 2017-11-15 PT PT178724290T patent/PT3541807T/pt unknown
- 2017-11-15 KR KR1020197017161A patent/KR102508739B1/ko active Active
- 2017-11-15 SM SM20210675T patent/SMT202100675T1/it unknown
- 2017-11-15 WO PCT/US2017/061875 patent/WO2018093953A1/en not_active Ceased
- 2017-11-15 SM SM20230494T patent/SMT202300494T1/it unknown
- 2017-11-15 EP EP21199077.5A patent/EP3964503B1/en active Active
- 2017-11-15 MY MYPI2019002687A patent/MY199386A/en unknown
- 2017-11-15 PL PL21199077.5T patent/PL3964503T3/pl unknown
- 2017-11-15 TN TNP/2019/000151A patent/TN2019000151A1/en unknown
- 2017-11-15 CR CR20190242A patent/CR20190242A/es unknown
- 2017-11-15 HR HRP20211863TT patent/HRP20211863T1/hr unknown
- 2017-11-15 SI SI201730987T patent/SI3541807T1/sl unknown
- 2017-11-15 GE GEAP201715091A patent/GEP20237559B/en unknown
- 2017-11-15 CA CA3043610A patent/CA3043610A1/en active Pending
- 2017-11-15 UA UAA201905624A patent/UA124585C2/uk unknown
- 2017-11-15 JP JP2019523672A patent/JP7042548B2/ja not_active Expired - Fee Related
- 2017-11-15 MX MX2019005767A patent/MX389459B/es unknown
- 2017-11-15 DK DK17872429.0T patent/DK3541807T3/da active
- 2017-11-15 CN CN201780083644.3A patent/CN110291083B/zh not_active Expired - Fee Related
- 2017-11-15 ES ES21199077T patent/ES2966939T3/es active Active
- 2017-11-15 HR HRP20231697TT patent/HRP20231697T1/hr unknown
- 2017-11-15 EP EP17872429.0A patent/EP3541807B1/en active Active
- 2017-11-15 HU HUE17872429A patent/HUE056973T2/hu unknown
- 2017-11-15 RS RS20231263A patent/RS65016B1/sr unknown
- 2017-11-15 RS RS20211501A patent/RS62665B1/sr unknown
- 2017-11-15 BR BR112019010003A patent/BR112019010003A2/pt not_active Application Discontinuation
- 2017-11-15 MA MA58133A patent/MA58133B1/fr unknown
- 2017-11-15 EA EA201991086A patent/EA201991086A1/ru unknown
-
2019
- 2019-05-12 IL IL266548A patent/IL266548A/en unknown
- 2019-05-14 PH PH12019501068A patent/PH12019501068A1/en unknown
- 2019-05-16 MX MX2022000249A patent/MX2022000249A/es unknown
- 2019-05-16 NI NI201900053A patent/NI201900053A/es unknown
- 2019-05-16 DO DO2019000120A patent/DOP2019000120A/es unknown
- 2019-05-16 CO CONC2019/0005045A patent/CO2019005045A2/es unknown
- 2019-05-16 CL CL2019001340A patent/CL2019001340A1/es unknown
- 2019-05-16 EC ECSENADI201935171A patent/ECSP19035171A/es unknown
- 2019-05-17 ZA ZA2019/03093A patent/ZA201903093B/en unknown
-
2021
- 2021-09-08 US US17/469,535 patent/US11993588B2/en active Active
- 2021-12-13 CY CY20211101092T patent/CY1124870T1/el unknown
-
2022
- 2022-03-08 JP JP2022035398A patent/JP7350117B2/ja active Active
-
2024
- 2024-01-29 CY CY20241100067T patent/CY1126586T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19035171A (es) | Formas cristalinas de un inhibidor de magl | |
| MX2023000085A (es) | Compuestos antiproliferativos y metodos para utilizarlos. | |
| CY1124088T1 (el) | Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος | |
| IL278854A (en) | Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile | |
| CY1124427T1 (el) | Συνθεση omecamtiv mecarbil | |
| UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
| AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
| BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
| MX2017013248A (es) | Compuesto del inhibidor fgfr4 cristalino y usos del mismo. | |
| HUE062726T2 (hu) | 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái | |
| CL2022002895A1 (es) | Síntesis de un inhibidor de la monoacilglicerol lipasa. | |
| CL2019000377A1 (es) | Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica. | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| CO6680652A2 (es) | Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina | |
| IL284665A (en) | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same | |
| AR104935A1 (es) | Formas cristalinas de un inhibidor de histona deacetilasa | |
| PY1976957A (es) | Formas cristalinas de un compuesto de quinazolina y sus sales de clorhidrato.- | |
| AR110998A1 (es) | Inhibidores de la tirosina cinasa de bruton | |
| AR103801A1 (es) | Formas cristalinas de un compuesto de pirrolopiridina | |
| CO2018000953A2 (es) | Asociación entre la 3 - [(3 - {[4- (4-morfolinilmetil) -1h-pirrol-2-il] metilen} -2-oxo-2,3-dihidro-1h-indol-5-il) metil ] -1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr | |
| MX2017000513A (es) | Cristal de derivado de azol-benceno. | |
| HK40051930A (en) | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile | |
| UA108342U (uk) | 7-н-бутил-8-n,n-діетиламіноетиламіно-3-метилксантину сукцинат, який виявляє діуретичну та аналгетичну дію | |
| EA201890806A1 (ru) | Ингибитор рецептора p2x7 |